Can Cannabis Users Self-Titrate Across Different Potencies? What Blood Verification Adds
Different amounts of cannabis flower did not necessarily produce different measured THC-related blood exposure in a preliminary naturalistic study. The finding supports investigating self-titration, rather than assuming product potency alone determines absorbed dose.
A three-day product assignment
Bidwell and colleagues enrolled 24 male cannabis users and asked them to use one of two legal-market products they purchased. The products differed in THC and CBD content. After three days, participants returned for blood collection and assessments following their final use.
Blood cannabinoid patterns supported adherence in 23 participants. One participant whose results did not match the assigned product was excluded. Exposure verification therefore materially affected the analyzed sample.
Amount used and exposure were not equivalent
The THC/CBD-product group reported using more flower than their usual amount. Nevertheless, the groups did not have significantly different THC-plus-metabolite blood levels. The mixed product was associated with lower craving, subjective effects, and selected circulating cytokines.
Those results are preliminary associations within a small, unblinded naturalistic design. They do not demonstrate that everyone precisely adjusts intake or that any CBD-containing product reliably prevents intoxication.
What should an exposure estimate include?
A flower’s labeled percentage must be distinguished from the amount consumed, delivery efficiency, elapsed time, and the chemical actually measured. A combined parent-plus-metabolite measure also should not be treated as parent THC alone.
The study’s main contribution includes feasibility of verifying product assignment in real-world use. Its cytokine findings do not establish treatment of inflammatory disease, and its exposure results do not certify driving safety. Product labels are one component of evidence, rather than a complete reconstruction of dose or function.
Related reading: how route and timing affect cannabis evidence.
Primary research
L. Cinnamon Bidwell; Raeghan Mueller; Sophie L. YorkWilliams; Sarah Hagerty; Angela D. Bryan; Kent E. Hutchison. A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains. Cannabis and Cannabinoid Research (2018). DOI: 10.1089/can.2017.0038.
